Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood cancer journal Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., Hua, Z., Stein, H., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, B. C., DeAngelo, D. J. 2017; 7 (2)
View details for DOI 10.1038/bcj.2017.1
View details for PubMedID 28157218
View details for PubMedCentralID PMC5386335